Breaking News Instant updates and real-time market news.

WBA

Walgreens Boots Alliance

$65.35

1.14 (1.78%)

, KR

Kroger

$24.94

0.2 (0.81%)

06:47
05/17/18
05/17
06:47
05/17/18
06:47

Walgreen, Kroger, Albertsons, HEB sue Allergan over Restasis, Reuters reports

U.S. retailers Walgreens (WBA), Kroger (KR), Albertson's and HEB Grocery are suing Allergan (AGN) accusing the drugmaker of antitrust violations for trying to stop competitors from selling generic versions of its dry-eye treatment Restasis, Reuters reports, citing the suit. The retailers claim Allergan illegally preserved its monopoly by securing illegal patents, suing rivals that challenged those patents and transferring the patents to a sovereign Native American tribe, New York's Saint Regis Mohawk Tribe, to avoid scrutiny by U.S. courts. Reference Link

WBA

Walgreens Boots Alliance

$65.35

1.14 (1.78%)

KR

Kroger

$24.94

0.2 (0.81%)

AGN

Allergan

$154.46

2.32 (1.52%)

  • 17

    May

WBA Walgreens Boots Alliance
$65.35

1.14 (1.78%)

04/02/18
MSCO
04/02/18
NO CHANGE
MSCO
Equal Weight
Morgan Stanley says may make sense for Walmart to play bigger role in healthcare
Morgan Stanley analyst Simeon Gutman estimates Walmart (WMT) generates about $20B in pharmacy sales annually, which he believes makes it the third largest U.S. pharmacy provider behind CVS (CVS) and Walgreens (WBA). Following a report from The Wall Street Journal that the company and Humana (HUM) were in merger talks, and subsequent reports from Reuters and Bloomberg that the two may only be discussing a broader partnership instead of a buyout deal, Gutman said that consolidation of other retailers and healthcare providers could put Walmart at a disadvantage and he believes it may make sense for Walmart to play a larger role in healthcare. He maintains an Equal Weight rating on Walmart shares.
04/24/18
LEER
04/24/18
NO CHANGE
LEER
Amazon shelving pharma supply efforts to hospitals not surprising, says Leerink
Leerink analyst David Larsen notes that Amazon (AMZN) is said to be shelving its pharmaceutical supply efforts to hospitals, which he does not see as a suprise given several barriers to entry. The consumer market has always been Amazon's core competency, though he expects it will be a long, gradual, and difficult process of building up an online drug portfolio with an initial focus likely on generics. The analyst believes the risk of Amazon entering retail in the near term is reduced significantly. Nonetheless, Larsen thinks risk remains longer term for retail pharmacies such as CVS (CVS) and Walgreens Boots Alliance (WBA).
04/17/18
MZHO
04/17/18
NO CHANGE
MZHO
Amazon news removes 'unprecedented overhang' on drug sellers, says Mizuho
After CNBC reported yesterday afternoon that Amazon (AMZN) has decided to shelve its plan to sell and distribute pharmaceutical products, Mizuho analyst Ann Hynes said she had thought Amazon's current logistics and distribution model would not translate into healthcare. However, based on conversations with investors, she believes the magnitude of the overhang that Amazon presented for drug distributors and retail pharmacies was "unprecedented." While drug pricing is still a concern, she notes that the CNBC report removes one overhang on the drug supply chain stocks. Hynes remain a buyer of CVS Health (CVS) and Walgreens (WBA) and keeps Neutral ratings on Rite Aid (RAD) as well as on drug distributors AmerisourceBergen (ABC), Cardinal Health (CAH) and McKesson (MCK).
04/03/18
JEFF
04/03/18
NO CHANGE
Target $85
JEFF
Buy
Walgreens fundamentals to eventually drive shares higher, says Jefferies
Jefferies analyst Brian Tanquilut says that while Walgreens Boots Alliance shares will likely behave like a deal stock with an overhang that limits near-term upside, fundamentals will eventually drive the stock higher over the longer term. The analyst lowered his price target for Walgreens to $85 from $93 and keeps a Buy rating on the name. He expects continued earnings beats from the company, and thinks investors will eventually be rewarded.
KR Kroger
$24.94

0.2 (0.81%)

04/13/18
OPCO
04/13/18
NO CHANGE
OPCO
Outperform
Low levels of food inflation to keep weighing on grocery names, Oppenheimer says
Following a government report this week that showed another month of soft food inflation data, Oppenheimer analyst Rupesh Parikh said he expects low food inflation to continue to weigh on grocery names, taking a "subdued" view into earnings for pure-play grocery names like Kroger (KR), National Grocers (NGVC), Sprouts Farmers Market (SFM) and Smart & Final Stores (SFS). Parikh's top picks across the broader grocery/discounter space remain Dollar General (DG) and Dollar Tree (DLTR), followed by Sprouts, he said. The analyst has an Outperform rating on Dollar General, Dollar Tree and Sprouts, and a Perform rating on Kroger, Natural Grocers, Smart & Final Stores and United Natural Foods (UNFI).
04/17/18
FBCO
04/17/18
INITIATION
FBCO
Outperform
Kroger initiated with an Outperform at Credit Suisse
04/17/18
FBCO
04/17/18
INITIATION
FBCO
Outperform
Kroger initiated with an Outperform at Credit Suisse
Credit Suisse analyst Judah Frommer initiated Kroger with an Outperform and $28 price target, saying the company's underappreciated assets should drive above-consensus sales growth.
05/10/18
MOFT
05/10/18
DOWNGRADE
MOFT
Neutral
Kroger downgraded to Neutral from Buy at MoffettNathanson (pre-open)
AGN Allergan
$154.46

2.32 (1.52%)

05/01/18
DBAB
05/01/18
NO CHANGE
Target $210
DBAB
Buy
Deutsche continues to like the setup for Allergan shares
Deutsche Bank analyst Gregg Gilbert acknowledges the uncertainty regarding Allergan's strategic review but says he continues to like the setup for the shares. The analyst his earnings estimates based primarily on the Q1 outperformance and accelerated share repurchase. He keeps a Buy rating on Allergan with a $210 price target.
05/01/18
WELS
05/01/18
NO CHANGE
Target $240
WELS
Outperform
Allergan price target lowered to $240 from $245 at Wells Fargo
Wells Fargo analyst David Maris lowered his price target for Allergan to $240 from $245 following Q1 results and as investors seem to remain uncertain about Allergan's strategic direction. The analyst reiterates an Outperform rating on the shares.
05/07/18
CANT
05/07/18
NO CHANGE
CANT
Cantor positive on Evolus, Revance on potential to take Botox share
The potential launches of Evolus' (EOLS) DWP-450 in 2018 and Revance Therapeutics' (RVNC) RT002 in 2020 has investors wondering if less expensive and longer lasting toxins could take meaningful share away from Allergan's (AGN) Botox, Cantor Fitzgerald analyst Louise Chen tells investors in a research note. After speaking with two physicians who use 500-864 vials of Botox per year in their practices, the analyst reiterates Overweight ratings on Evolus and Revance and a Neutral rating on Allergan. Both doctors, who use Allergan's Botox in 95%-plus of their patients, said they would switch a large amount of their practice over to less expensive and/or longer acting toxins, if they are approved, Chen writes.
05/16/18
WELS
05/16/18
NO CHANGE
WELS
Outperform
Evolus CRL good news for Allergan, says Wells Fargo
Wells Fargo analyst David Maris noted that Evolus (EOLS) received a Complete Response Letter for its application for cosmetic neuro toxin candidate DWP-450, which he views as good news for Allergan (AGN) as the delay means Evolus will miss the 2018-2019 holiday season, which he points out is an important selling season for Botox. Maris, who also thinks Allergan may be able to use the CRL to "counter-detail" DWP-450 with doctors if the product does reach market, keeps an Outperform rating on Allergan shares.

TODAY'S FREE FLY STORIES

03:15
11/15/18
11/15
03:15
11/15/18
03:15
General news
FX Action: USD-CAD has settled in the lower 1.3200s »

FX Action: USD-CAD has…

02:30
11/15/18
11/15
02:30
11/15/18
02:30
General news
FX Update: The Dollar has traded broadly softer »

FX Update: The Dollar has…

01:50
11/15/18
11/15
01:50
11/15/18
01:50
General news
Asian Market Wrap: »

Asian Market Wrap:…

APTX

Aptinyx

$24.75

-0.76 (-2.98%)

21:40
11/14/18
11/14
21:40
11/14/18
21:40
Initiation
Aptinyx initiated at Cantor Fitzgerald »

Aptinyx initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OVID

Ovid Therapeutics

$4.75

-0.42 (-8.12%)

21:39
11/14/18
11/14
21:39
11/14/18
21:39
Initiation
Ovid Therapeutics initiated at Cantor Fitzgerald »

Ovid Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

AXSM

Axsome Therapeutics

$2.82

-0.07 (-2.42%)

21:38
11/14/18
11/14
21:38
11/14/18
21:38
Initiation
Axsome Therapeutics initiated at Cantor Fitzgerald »

Axsome Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DNLI

Denali Therapeutics

$17.53

0.24 (1.39%)

21:37
11/14/18
11/14
21:37
11/14/18
21:37
Initiation
Denali Therapeutics initiated at Cantor Fitzgerald »

Denali Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OTIC

Otonomy

$2.34

-0.07 (-2.90%)

21:35
11/14/18
11/14
21:35
11/14/18
21:35
Initiation
Otonomy initiated at Cantor Fitzgerald »

Otonomy initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

AAPL

Apple

$186.81

-5.42 (-2.82%)

20:46
11/14/18
11/14
20:46
11/14/18
20:46
Hot Stocks
Apple supplier AMS AG discontinues FY18 targets »

Ams updates its fourth…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

WEI

Weidai

$0.00

(0.00%)

20:33
11/14/18
11/14
20:33
11/14/18
20:33
Syndicate
Weidai 4.5M share IPO priced at $10.00 »

The deal was priced at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

CPB

Campbell Soup

$39.16

-0.1 (-0.25%)

20:31
11/14/18
11/14
20:31
11/14/18
20:31
Hot Stocks
Campbell Soup responds to ISS regarding board elections »

Campbell Soup issued the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

CRM

Salesforce

$129.25

-2.93 (-2.22%)

20:25
11/14/18
11/14
20:25
11/14/18
20:25
Periodicals
Breaking Periodicals news story on Salesforce »

Salesforce to accommodate…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 20

    Nov

  • 27

    Nov

  • 27

    Nov

  • 28

    Nov

  • 29

    Nov

  • 06

    Dec

  • 11

    Dec

  • 03

    Mar

WMT

Walmart

$101.58

-1.37 (-1.33%)

, JCP

J.C. Penney

$1.23

-0.05 (-3.91%)

20:25
11/14/18
11/14
20:25
11/14/18
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

WMT

Walmart

$101.58

-1.37 (-1.33%)

JCP

J.C. Penney

$1.23

-0.05 (-3.91%)

BERY

Berry Global

$45.91

-0.49 (-1.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 15

    Nov

  • 15

    Nov

BHVN

Biohaven Pharmaceutical

$33.70

-3.18 (-8.62%)

19:53
11/14/18
11/14
19:53
11/14/18
19:53
Recommendations
Biohaven Pharmaceutical analyst commentary at Piper Jaffray »

Biohaven Pharmaceutical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 14

    Nov

  • 15

    Nov

  • 27

    Nov

LOXO

Loxo Oncology

$143.69

-15.62 (-9.80%)

19:51
11/14/18
11/14
19:51
11/14/18
19:51
Initiation
Loxo Oncology initiated at Raymond James »

Loxo Oncology initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 15

    Nov

  • 26

    Nov

  • 27

    Nov

OCUL

Ocular Therapeutix

$5.06

-0.25 (-4.71%)

19:50
11/14/18
11/14
19:50
11/14/18
19:50
Initiation
Ocular Therapeutix initiated at Raymond James »

Ocular Therapeutix…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 28

    Dec

VYGR

Voyager Therapeutics

$11.25

-0.54 (-4.58%)

19:49
11/14/18
11/14
19:49
11/14/18
19:49
Upgrade
Voyager Therapeutics rating change at Raymond James »

Voyager Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

GLPG

Galapagos NV

$103.79

1.03 (1.00%)

19:48
11/14/18
11/14
19:48
11/14/18
19:48
Initiation
Galapagos NV initiated at Raymond James »

Galapagos NV initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COPY

CopyTele

$0.00

(0.00%)

19:47
11/14/18
11/14
19:47
11/14/18
19:47
Upgrade
CopyTele rating change at BMO Capital »

CopyTele upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VICI

VICI Properties

$21.43

-0.04 (-0.19%)

19:40
11/14/18
11/14
19:40
11/14/18
19:40
Syndicate
VICI Properties 30M share Secondary priced at $21.00 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

WHD

Cactus

$32.37

-0.7 (-2.12%)

19:37
11/14/18
11/14
19:37
11/14/18
19:37
Hot Stocks
Cactus names Stephen Tadlock new CFO »

Cactus announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RVLT

Revolution Lighting

$1.42

(0.00%)

19:32
11/14/18
11/14
19:32
11/14/18
19:32
Hot Stocks
Revolution Lighting receives revised $1.50 per share proposal from RVL LLC »

Revolution Lighting…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GE

General Electric

$8.34

-0.265 (-3.08%)

19:20
11/14/18
11/14
19:20
11/14/18
19:20
Periodicals
General Electric withdraws from Nigeria rail concession, Reuters says »

GE has withdrawn from a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BCSF

Bain Capital Specialty Finance

$0.00

(0.00%)

19:11
11/14/18
11/14
19:11
11/14/18
19:11
Syndicate
Bain Capital Specialty Finance 7.5M share IPO price $20.25 »

The deal priced at the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

TSLA

Tesla

$344.07

5.36 (1.58%)

19:07
11/14/18
11/14
19:07
11/14/18
19:07
Periodicals
Tesla Model 3 owners experience issues in cold weather, Electrek says »

Tesla Model 3 will face…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 19

    Nov

  • 19

    Nov

  • 13

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.